PET scan study of heart filling and blood flow in sickle cell
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study uses a PET scan to look for links between abnormal heart “filling” problems and how well blood reaches the heart muscle in people with sickle cell disease. The results may help explain early heart changes in sickle cell and guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 21 years old
- Be Black
- Have sickle cell disease with HbSS or HbS beta-zero thalassemia (HbSβ0thalassemia) genotype
- Fall into one group based on your echocardiogram: diastolic dysfunction (3+ abnormal measures) or no diastolic dysfunction (2 or fewer)
- If you are a healthy control, you must not have any sickle cell genotype and must have 2 or fewer abnormal diastolic measures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses MRI scans to understand how the brain and blood vessels are affected in children with sickle cell disease, including before and after certain treatments. It also includes healthy children for comparison and may help improve future monitoring and care.
This trial tests early screening and treatment to prevent heart problems in people with sickle cell disease. It focuses on those with high iron levels or heart symptoms, using regular heart imaging to monitor and treat complications early.
This study measures how well blood flows through brain arteries in children with sickle cell disease using a noninvasive ultrasound test. It may help doctors better understand stroke risk and how treatments like hydroxyurea or recent care affect blood flow.
This trial tests whether adding acupuncture to standard pain treatments can help manage pain in people with sickle cell disease. It involves brain scans, questionnaires, and acupuncture sessions to see if this approach reduces pain and improves quality of life.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.